See more : TMT (INDIA) LTD. (TMTIND-B1.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Torii Pharmaceutical Co., Ltd. (4551.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Torii Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Athena Consumer Acquisition Corp. (ACAQ-UN) Income Statement Analysis – Financial Results
- Hudson Executive Investment Corp. III (HIII) Income Statement Analysis – Financial Results
- Standard Life Investments Property Income Trust Limited (SLI.L) Income Statement Analysis – Financial Results
- Rock Tech Lithium Inc. (RCKTF) Income Statement Analysis – Financial Results
- Capri Holdings Limited (CPRI) Income Statement Analysis – Financial Results
Torii Pharmaceutical Co., Ltd. (4551.T)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.torii.co.jp
About Torii Pharmaceutical Co., Ltd.
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent used for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; allergen immunotherapy tablets comprising CEDARCURE and MITICURE; and CORECTIM, a topical janus kinase (JAK) inhibitor. It markets its products primarily through medical representatives for medical professionals. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 54.64B | 48.89B | 46.99B | 41.70B | 43.00B | 62.55B | 64.13B | 60.21B | 62.38B | 43.50B | 58.11B | 52.29B | 48.72B | 45.34B | 42.42B | 37.35B | 40.84B | 39.58B | 40.48B | 41.91B |
Cost of Revenue | 29.85B | 25.52B | 22.65B | 19.96B | 20.70B | 31.84B | 31.29B | 30.29B | 30.81B | 20.59B | 26.27B | 22.84B | 20.54B | 18.60B | 15.98B | 13.65B | 16.25B | 15.37B | 14.90B | 15.61B |
Gross Profit | 24.79B | 23.38B | 24.34B | 21.74B | 22.30B | 30.71B | 32.84B | 29.92B | 31.56B | 22.92B | 31.84B | 29.45B | 28.18B | 26.73B | 26.43B | 23.70B | 24.59B | 24.20B | 25.58B | 26.31B |
Gross Profit Ratio | 45.38% | 47.81% | 51.80% | 52.13% | 51.85% | 49.09% | 51.21% | 49.70% | 50.60% | 52.68% | 54.80% | 56.32% | 57.84% | 58.97% | 62.32% | 63.46% | 60.21% | 61.15% | 63.19% | 62.76% |
Research & Development | 3.49B | 1.66B | 832.00M | 596.00M | 2.96B | 4.14B | 4.61B | 4.65B | 5.24B | 3.40B | 6.66B | 7.82B | 4.63B | 5.99B | 1.61B | 1.19B | 1.83B | 1.77B | 911.00M | 454.00M |
General & Administrative | 12.43B | 1.71B | 0.00 | 0.00 | 0.00 | 0.00 | 581.00M | 564.00M | 570.00M | 585.00M | 1.13B | 2.33B | 2.38B | 3.34B | 3.32B | 2.33B | 2.29B | 5.75B | 5.90B | 5.87B |
Selling & Marketing | 1.58B | 1.58B | 4.19B | 3.32B | 2.83B | 5.17B | 5.09B | 5.00B | 5.15B | 3.62B | 4.04B | 3.76B | 4.18B | 3.78B | 3.68B | 3.31B | 3.66B | 0.00 | 0.00 | 0.00 |
SG&A | 16.05B | 1.58B | 4.19B | 3.32B | 2.83B | 5.17B | 5.09B | 5.00B | 5.15B | 3.62B | 4.04B | 6.10B | 6.56B | 7.12B | 7.01B | 5.64B | 5.95B | 5.75B | 5.90B | 5.87B |
Other Expenses | 219.00M | 14.59B | 14.66B | 13.08B | 15.07B | 24.00M | 58.00M | 72.00M | 49.00M | 37.00M | 32.00M | 37.00M | 39.00M | 55.00M | 44.00M | 56.00M | 75.00M | 110.00M | -18.00M | 2.58B |
Operating Expenses | 19.76B | 17.84B | 19.68B | 17.00B | 20.86B | 25.75B | 26.56B | 26.10B | 26.64B | 18.88B | 26.85B | 26.65B | 24.02B | 20.80B | 16.31B | 15.05B | 15.90B | 15.50B | 14.77B | 14.47B |
Cost & Expenses | 49.60B | 43.35B | 42.33B | 36.96B | 41.56B | 57.60B | 57.85B | 56.38B | 57.46B | 39.47B | 53.12B | 49.49B | 44.56B | 39.41B | 32.29B | 28.70B | 32.15B | 30.87B | 29.67B | 30.08B |
Interest Income | 287.00M | 167.00M | 144.00M | 132.00M | 138.00M | 53.00M | 27.00M | 39.00M | 83.00M | 60.00M | 89.00M | 112.00M | 117.00M | 134.00M | 196.00M | 297.00M | 278.00M | 143.00M | 52.00M | 29.00M |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.05B | 1.00M | 0.00 | 0.00 | 362.00M | 0.00 | 23.00M | 1.00M | 1.00M | 1.00M | 1.00M | 6.99B | 6.80B | 6.58B | 4.34B |
Depreciation & Amortization | 459.00M | 252.00M | 279.00M | 461.00M | 807.00M | 843.00M | 1.08B | 1.18B | 1.46B | 924.00M | 1.09B | 1.06B | 1.19B | 1.39B | 1.41B | 1.42B | 1.22B | 1.13B | 1.01B | 958.00M |
EBITDA | 5.83B | 5.98B | 5.05B | 4.69B | 38.51B | 3.88B | 7.46B | 5.24B | 6.38B | 5.07B | 7.07B | 3.86B | 6.25B | 3.89B | 8.40B | 7.46B | 9.92B | 13.37B | 8.54B | 11.07B |
EBITDA Ratio | 10.67% | 12.38% | 11.32% | 13.41% | 6.22% | 9.78% | 11.81% | 8.87% | 10.57% | 11.65% | 10.69% | 7.67% | 11.36% | 16.53% | 27.77% | 27.92% | 33.27% | 33.78% | 37.35% | 36.76% |
Operating Income | 5.04B | 5.54B | 4.66B | 4.74B | 1.43B | 4.95B | 6.28B | 3.82B | 4.92B | 4.03B | 4.99B | 2.79B | 4.15B | 1.84B | 6.13B | 4.90B | 5.14B | 12.24B | 7.61B | 8.50B |
Operating Income Ratio | 9.22% | 11.33% | 9.91% | 11.36% | 3.33% | 7.92% | 9.79% | 6.34% | 7.89% | 9.27% | 8.58% | 5.34% | 8.52% | 4.07% | 14.44% | 13.12% | 12.58% | 30.92% | 18.79% | 20.28% |
Total Other Income/Expenses | 557.00M | 182.00M | 111.00M | -513.00M | 36.27B | -1.92B | 92.00M | 237.00M | 339.00M | -251.00M | 146.00M | 135.00M | 901.00M | -5.00M | 215.00M | 1.14B | 239.00M | -3.27B | -69.00M | 1.62B |
Income Before Tax | 5.59B | 5.72B | 4.77B | 4.23B | 37.70B | 3.03B | 6.37B | 4.06B | 5.26B | 3.78B | 5.13B | 2.93B | 5.05B | 1.84B | 6.34B | 6.04B | 5.38B | 5.43B | 7.54B | 10.12B |
Income Before Tax Ratio | 10.24% | 11.70% | 10.15% | 10.13% | 87.68% | 4.84% | 9.94% | 6.74% | 8.43% | 8.69% | 8.83% | 5.60% | 10.37% | 4.06% | 14.95% | 16.17% | 13.17% | 13.73% | 18.62% | 24.13% |
Income Tax Expense | 1.47B | 1.78B | 1.39B | 729.00M | 10.33B | 1.87B | 1.66B | 1.22B | 1.73B | 1.36B | 1.78B | 1.08B | 2.44B | 901.00M | 2.70B | 2.56B | 2.41B | 2.41B | 3.36B | 4.32B |
Net Income | 4.12B | 3.94B | 3.37B | 3.50B | 27.37B | 1.16B | 4.72B | 2.84B | 3.53B | 2.42B | 3.35B | 1.85B | 2.61B | 937.00M | 3.64B | 3.48B | 2.97B | 3.03B | 4.18B | 5.79B |
Net Income Ratio | 7.54% | 8.07% | 7.18% | 8.38% | 63.65% | 1.86% | 7.36% | 4.72% | 5.65% | 5.56% | 5.77% | 3.54% | 5.36% | 2.07% | 8.59% | 9.31% | 7.26% | 7.65% | 10.32% | 13.82% |
EPS | 146.57 | 140.38 | 120.11 | 124.47 | 974.99 | 41.49 | 168.22 | 100.41 | 124.65 | 85.50 | 118.47 | 65.36 | 92.27 | 33.11 | 128.69 | 122.84 | 104.83 | 106.99 | 146.76 | 203.83 |
EPS Diluted | 146.57 | 140.38 | 120.11 | 124.46 | 974.99 | 41.49 | 168.22 | 100.41 | 124.65 | 85.50 | 118.47 | 65.36 | 92.27 | 33.11 | 128.69 | 122.84 | 104.83 | 106.99 | 146.76 | 203.83 |
Weighted Avg Shares Out | 28.10M | 28.10M | 28.09M | 28.08M | 28.07M | 28.06M | 28.05M | 28.28M | 28.30M | 28.29M | 28.30M | 28.30M | 28.30M | 28.30M | 28.30M | 28.30M | 28.31M | 28.31M | 28.31M | 28.31M |
Weighted Avg Shares Out (Dil) | 28.10M | 28.10M | 28.09M | 28.08M | 28.07M | 28.06M | 28.05M | 28.28M | 28.30M | 28.29M | 28.30M | 28.30M | 28.30M | 28.30M | 28.30M | 28.30M | 28.31M | 28.31M | 28.31M | 28.31M |
Source: https://incomestatements.info
Category: Stock Reports